Discontinued — last reported Q3 '23
Products & Services · Amortization
Alliance revenue - Lenvima — Amortization
This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
StatementSegment
CategoryProfitability
SignalLower is better
VolatilityStable
First reportedQ1 2023
Last reportedQ3 2023
How to read this metric
An increase indicates higher historical acquisition costs or a shorter remaining useful life for the intangible assets, while a decrease suggests assets are becoming fully amortized.
Detailed definition
This metric represents the periodic non-cash expense recognized to allocate the cost of intangible assets acquired throu...
Peer comparison
Comparable to amortization of acquired intangible assets or developed technology assets reported by other pharmaceutical companies in collaborative licensing arrangements.
Metric ID:
mrk_segment_alliance_revenue_lenvima_amortizationHistorical Data
3 periods
| Q1 '23 | Q2 '23 | Q3 '23 | |
|---|---|---|---|
| Value | $72.00M | $0.00 | $81.00M |
| QoQ Change | — | -100.0% | — |
Range$0.00 – $81.00M
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Merck & Co.'s alliance revenue - lenvima — amortization?
- Merck & Co. (MRK) reported alliance revenue - lenvima — amortization of $81.00M in Q3 2023.
- What does alliance revenue - lenvima — amortization mean?
- The annual non-cash expense recognized for the gradual write-down of intangible assets related to a specific product alliance.